Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926634 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
A Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06926634: Recruiting Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
NCT06926634 is a Phase 2 study of High Grade Neuroendocrine Neoplasms that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926634, a Phase 2 study of High Grade Neuroendocrine Neoplasms, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
Primary Outcome
PFS is defined as the time from the date of initiation of zanzalintinib treatment to progression or death, whichever occurs first. The alive patients without progression are censored at the last follow-up.
Conditions Studied
Interventions
- DRUG Zanzalintinib
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 2 |
What NCT06926634 shows while recruiting
NCT06926634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with High Grade Neuroendocrine Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT06926634 reports a single indexed study location in Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT06926634 about?
NCT06926634 is a clinical study titled "Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)". The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
What is the current status of trial NCT06926634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-09. Estimated completion is 2034-12-31.
What conditions does trial NCT06926634 study?
This clinical trial studies the following conditions: High Grade Neuroendocrine Neoplasms.
What interventions are being tested in trial NCT06926634?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06926634?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926634 being conducted?
This trial has 2 study locations across Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Neuroendocrine Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06926634's enrollment target sits among peer trials
32 1563rd of 2000 higher than 424 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI